指南与共识慢阻肺间质性肺疾病

α1-抗胰蛋白酶缺乏相关肺病的诊断与治疗:澳大利亚与新西兰胸科学会立场声明

Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand.
指南 / 共识 · Respirology · 2020-02-06

该立场声明由澳大利亚与新西兰胸科学会制定,综述AATD相关肺病诊断与治疗证据,采用系统评价评估AAT增强治疗疗效与不良事件,并用GRADE方法形成推荐,同时涵盖检测时机、监测、杂合子疾病、药物与非药物及手术治疗、遗传咨询与登记注册等议题。

要点

  • AATD相关肺气肿常未被诊断,应关注检测时机与方法。
  • AAT增强治疗为静脉输注人血浆来源AAT蛋白,疗效存争议。
  • 澳新已批准AAT增强治疗但政府暂未补贴。

核心结论

  • AATD相关肺病患者常未获诊断与专科照护,需系统识别与管理。
  • AAT增强治疗临床疗效存争议,澳新已批准但未获政府补贴。

研究设计与样本

  • 澳大利亚与新西兰胸科学会立场声明。
  • AAT增强治疗疗效与不良事件采用系统评价,并以GRADE方法从证据形成推荐。

主要发现

  • AATD是常见遗传病,增加肺气肿与肝病风险。
  • AAT增强治疗为静脉输注混合血制品来源的外源性AAT蛋白。
  • 澳新监管机构近期允许AAT增强治疗,但两国政府目前未补贴。

关键数值与推荐

  • 声明涵盖AATD检测时机与方法、诊断技术变化、进展监测、杂合子疾病及药物与非药物和重症手术选择。
  • 声明还涉及遗传咨询、患者支持组织、肝病监测及建立澳新AATD国家登记注册。

临床怎么用

  • 呼吸科医生应识别AATD相关肺病并适时检测,避免漏诊。
  • 治疗决策需结合AAT增强治疗证据、可及性与费用状况。
  • 管理需兼顾遗传咨询、肝病监测与患者支持资源。

局限性

  • AAT增强治疗临床疗效仍有争议。
  • 澳新政府目前未补贴AAT增强治疗,可及性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AATD is a common inherited disorder associated with an increased risk of developing pulmonary emphysema and liver disease. Many people with AATD-associated pulmonary emphysema remain undiagnosed and therefore without access to care and counselling specific to the disease. AAT augmentation therapy is available and consists of i.v. infusions of exogenous AAT protein harvested from pooled blood products. Its clinical efficacy has been the subject of some debate and the use of AAT augmentation therapy was recently permitted by regulators in Australia and New Zealand, although treatment is not presently subsidized by the government in either country. The purpose of this position statement is to review the evidence for diagnosis and treatment of AATD-related lung disease with reference to the Australian and New Zealand population. The clinical efficacy and adverse events of AAT augmentation therapy were evaluated by a systematic review, and the GRADE process was employed to move from evidence to recommendation. Other sections address the wide range of issues to be considered in the care of the individual with AATD-related lung disease: when and how to test for AATD, changing diagnostic techniques, monitoring of progression, disease in heterozygous AATD and pharmacological and non-pharmacological therapy including surgical options for severe disease. Consideration is also given to broader issues in AATD that respiratory healthcare staff may encounter: genetic counselling, patient support groups, monitoring for liver disease and the need to establish national registries for people with AATD in Australia and New Zealand.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Dummer J, Dobler CC, Holmes M, et al. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 2020. PMID: 32030868. doi:10.1111/resp.13774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。